Background: Osteosarcoma (OSA) is a common bone tumor of mesenchymal origin in dogs.
| INTRODUCTION
Osteosarcoma (OSA) is the most common primary bone malignancy in dogs. Most tumors affect the appendicular skeleton, and the standard of care involves amputation of the affected limb with adjuvant chemotherapy. 1 Current research efforts are aimed at delaying pulmonary metastasis and the onset of chemoresistance.
The high metabolic demand of cancer cells promotes aerobic glycolysis irrespective of oxygen tension, a phenomenon well known as the Warburg effect. 2 This metabolic stress has been linked to tumor
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acidosis and hypoxia, hallmarks of solid tumors that contribute to increased immune evasion and chemoresistance. The development and maintenance of an intracellular pH gradient in cancer cells can be attributed, at least in part, to the action of sodium-hydrogen exchangers (NHEs). 3 Sodium-hydrogen exchangers are ubiquitous, adenosine triphosphate (ATP)-independent antiporters that exchange Na + for H + at 1 : 1 stoichiometry. Physiologically, NHEs regulate pH homeostasis and cellular response to mitogens and are critical for acid-base balance and sodium reabsorption. 4 NHE1 is the most widely expressed isoform, which, under low oxygen tension, is upregulated by hypoxia-inducible factors (HIFs), in particular HIF-1α. 5 The amiloride family of drugs are inhibitors of NHEs, and chemical substitutions increase the affinity for inhibition of the exchanger. Amiloride hydrochloride (amiloride) is the only FDA-approved NHE inhibitor.
Tumor acidosis in solid tumors contributes to acquire chemoresistance under selective pressures. 6 Comparable to the reported evolution of multidrug resistance transporters, studies in human cancer cells now independently show that common chemotherapeutics, such as doxorubicin, 7 mitoxantrone, 8 and vincristine, 9 are actively sequestered within acidic lysosomes. This sequestration prevents these drugs from exerting their DNA damaging or crosslinking effects and leads to their eventual degradation within cancer cells. Likewise, platinum agents, such as cisplatin and carboplatin, are actively transported into lysosomes through the endosomal expression of copper transporters. 10 As such, targeting proton pumps responsible for endosomal acidification has been suggested to improve chemotherapy response in cancer cells. 
| Crystal violet cytotoxicity assay
The half-maximal inhibitory concentration (IC50) for all drugs tested was determined systematically by the crystal violet cytotoxicity assay. Half-maximal inhibitory concentration curves were fit by nonlinear regression and averaged by experiments conducted in triplicate. Compensation was set for each data set to account for spillover between FITC and PI emission overlap (FL1 and FL3 channels).
| Combination index computations

| Immunoblotting
The following antibodies were purchased from Cell Signaling BSA (VWR International, Radnor, Pennsylvania) in TBST (for p-Akt).
Secondary antibodies were conjugated to horseradish peroxidase for chemiluminescence imaging. Coupling efficiency was defined as the ratio of the ATP production rate to the basal respiration rate. Maximal respiration was defined as the maximum OCR after FCCP injection, minus rates of nonmitochondrial respiration.
| Immunofluorescence
| Statistical and software analysis
Statistical testing was performed using GraphPad Prism 6 (GraphPad Software Inc, La Jolla, California), including linear or nonlinear regression, one-way or two-way ANOVA, unpaired t tests, and multiple comparisons tests. Means were reported with SD for descriptive statistics. Statistically insignificant differences in cell viability were observed for amiloride plus carboplatin when compared to amiloride treatment alone (P = .24), and significant decreases were observed when compared to carboplatin treatment alone (P = .01; Figure 2B ).
Pharmacological synergism (CI < 1) was observed with amiloride plus doxorubicin combination treatment. In amiloride plus doxorubicintreated groups, the lowest CI observed was 0.43 AE 0.13 with the lowest combination dose, significantly lower than the CI of 0.98 AE 0.13 at the highest dose (P < .05; Figure 2C Combination treatment with high-dose amiloride (300 μM) and pifithrin-μ (3 nM) rescued D17, Abrams, and Dharma cells from amiloride-induced reductions in cell viability. Significantly increased cell viability was observed with the drug combination compared to treatment with high dose amiloride alone (P < .05 for D17 and Abrams, P < .01 for Dharma; Figure 4D ). Furthermore, treatment with pifithrin-μ alone did not result in significant decreases in cell viability compared to the vehicle control (P = .70) ( Figure 4D ). Significance was reported at *P < .05, **P < .01, ***P < .001, ****P < .0001. OSA, osteosarcoma; PI, propidium iodide Figure 6A ). Exposure to saturating levels of glucose and oligomycin amplified the glycolytic output, and 2-DG exposure inhibited glycolytic output. In the mitochondrial stress test, amiloride exposure had no significant effect on OCR after basal readings (P = .28). However, upon FCCP uncoupling of the mitochondria during oxidative phosphorylation, spare capacity and maximal respiration were decreased, when compared to the vehicle control (P < .0001) ( Figure 6B ).
Measurements of ECAR readings during the first 45 minutes of the glycolytic test revealed a linear relationship between ECAR and
dose by regression analysis ( Figure 7A ). Consistent with this model, a significant reduction in ECAR (P < .05) was observed after high-dose amiloride treatment compared to vehicle ( Figure 7B ). Coupling efficiency (the ratio of ATP production rate to the basal respiration rate; Figure 7C ) and maximal respiration rates ( Figure 7D ) were both significantly reduced in a dose-dependent manner with amiloride treatment compared to the vehicle control (P < .0001). Basal readings of amiloride-treated cells revealed a metabolic switch from an aerobic to quiescent phenotype ( Figure 7E ). Oligomycin exposure also resulted in a metabolic shift towards quiescence ( Figure 7F ).
| DISCUSSION
To investigate acidification as a potential therapeutic target, we determined the effects of amiloride on carboplatin and doxorubicin response in canine OSA cells. After demonstrating that amiloride decreases cell viability in a dose-dependent manner, we evaluated its pharmacological synergism with carboplatin and doxorubicin (Figure 1 ). Based on CI ImageJ/Fiji image analysis. Native images were taken at 10x/0.7 aperture, the regions of interest (ROI) were defined and quantified using ImageJ. N = 3 per group, with mean AE SD. Significance was reported at *P < .05 and **P < .01. OSA, osteosarcoma superior adjuvant chemotherapy protocol currently exists, although single-agent carboplatin may often be chosen for dogs due its relative ease of administration and better tolerability, including lack of cardiotoxicity compared to doxorubicin and reduced nephrotoxicity compared to cisplatin. 24 Despite this potential carboplatin preference, if doxorubicin plus amiloride were to be proven more effective than either doxorubicin or carboplatin alone in clinical trial evaluation, this result could lead to a superior chemotherapy protocol choice for OSA treatment in dogs.
After cell viability results suggested synergism between amiloride and doxorubicin in combination treatment, we determined the effect of this combination on apoptosis ( Figure 3 ). As expected, combination treatment with doxorubicin significantly increased early apoptosis in canine OSA cells compared to doxorubicin or vehicle treatment alone.
To elucidate potential mechanisms behind amiloride-induced increases in apoptosis, we investigated molecular targets that could be activated during apoptosis. Previous studies that have suggested indirect, downstream effects of amiloride on Akt signaling and p53 signaling prompted investigation into this pathway in canine OSA. 25 Up to 50% of OSA tumors have mutated TP53. 26 Because amiloride exhibits antimyeloma activity and synergizes with dexamethasone, melphalan, lenalidomide, and pomalidomide, 18 we investigated changes in p53 signaling during amiloride-induced apoptosis in canine OSA cells and the downstream impact on pro-and anti-apoptotic family members (Figure 4 ). Upon exposure to amiloride, the pro-apoptotic family member Bax was upregulated, whereas the anti-apoptotic protein Bcl-xL was downregulated in a dose-dependent manner, suggesting that amiloride potentiates p53-dependent apoptosis. Pharmacological disruption of p53 transloca- Warburg metabolism. 28 We have determined with the Seahorse analyzer that under basal conditions, canine OSA cells can be considered to be quite glycolytic, with ECAR rates above 50 mpH/min ( Figure 6 ).
By performing energetic stress tests, we further showed that amiloride decreased ECAR in a dose-dependent manner, suggesting an inhibition of proton extrusion ( Figure 7 ). Glycolytic capacity is inferred from the extracellular production of protons, and reduced NHE activity can contribute to reduced proton extrusion through the endolysosomal pathway, 29 a gradient that leads to extracellular acidification. 
| Limitations
Amiloride was originally discovered as MK-870 for correcting the profound hypokalemia and alkalosis induced by thiazide and other diuretics. 31 Since its discovery, it was tested in a canine cardiac study, where a blood concentration of 0.2 μmoL/mL, corresponding to 200 μmol/L was used to perfuse isolated AV node, SA node, and papillary muscle preparations. 12 At this dose, amiloride prolonged the functional refractory period at atrial pacing rates of 100, 150, and 200 stimuli/min. The study also noted that a blood concentration of 0.2 μmoL/mL corresponded to 46 μg/mL. Earlier studies of MK-870 in guinea pigs in 1977 have dose escalated up to 200 μg/mL but found no significant effects in the upstroke velocity of ventricular muscle. 32 To the best of our knowledge, although amiloride has been extensively tested in the dog, no specific pharmacokinetic (PK) study of amiloride in the dog is published. Rather, variables such as renal clearance and sodium excretion have been widely reported in dogs given high doses of amiloride. 33 In human PK studies, peak reported serum concentrations (C max ) of amiloride varies depending on the route of administration and dose. A single oral 10 mg dose leads to a C max of 20.6 AE 10.0 ng/mL in adults, 34 and an oral dose of 20 mg alone leads to a C max of 47.5 AE 13.0 ng/mL 35 both achieved shortly after 4 hours. In contrast, PK data in rats demonstrates that an amiloride of 10 mg/kg results in a C max of 390.0 ng/mL after 4 hours. 36 From human PK data, we propose that there could be limitations as to how much amiloride could be given to dogs, especially on a consistent basis in oncology practice. Significance was recorded at *P < .05, **P < .01, ****P < .0001. ECAR, extracellular acidification rates; OCR, oxygen consumption rates Although we tested both low and high doses of amiloride typically used in in vitro doses, we found from CI calculations that the strongest synergism with doxorubicin was achieved at the lowest doses of amiloride that were tested ( Figure 2C ). Therefore, to achieve a potential sensitization effect in vivo, it might not be necessary to doseescalate to the highest in vitro doses tested in this study. Treatment of mice with amiloride at a dose of 15 mg/kg/d resulted in significant antitumor efficacy in a model of multiple myeloma. 18 In comparison to early pharmacological studies in dogs with doses of 8 mg/kg/day, similar doses could be applied in combination with chemotherapy in the clinical setting. 33 Overall, the outstanding limitation of using in vitro doses is that the effects of amiloride observed might not translate to the same effects observed in vivo. Thus, the clinical evaluation of amiloride as a repurposed drug in an oncology setting would likely proceed in a dose-escalation format, and possibly in combination with chemotherapy, to maximize any potential chemosensitization benefit.
Apart from NHE targeting, other off-targets of amiloride have been documented, including its competitive inhibition of the urokinase plasminogen activator (uPA) and the epithelial sodium channel (ENaC). 37, 38 The uPA axis has been recently causally associated with the progression of OSA from a nonmetastatic to metastatic phenotype. 39 Thus, the potentiation of doxorubicin cytotoxicity by amiloride at high doses could extend beyond inhibition of the transporter itself.
Although the goal of this study was to evaluate the impact of amiloride on chemotherapy response in canine OSA cells, it can be hypothesized that amiloride also inhibits uPA to decrease invasion in canine 
